Free Trial
OTCMKTS:AZNCF

AstraZeneca (AZNCF) Stock Price, News & Analysis

AstraZeneca logo
$141.90
-7.60 (-5.08%)
(As of 10/31/2024 ET)

About AstraZeneca Stock (OTCMKTS:AZNCF)

Key Stats

Today's Range
$141.90
$144.05
50-Day Range
$147.37
$175.00
52-Week Range
$118.16
$175.00
Volume
1,307 shs
Average Volume
2,711 shs
Market Capitalization
N/A
P/E Ratio
173.90
Dividend Yield
1.97%
Price Target
N/A
Consensus Rating
N/A

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
6th Percentile Overall Score

AZNCF MarketRank™: 

AstraZeneca scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AstraZeneca is 183.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 135.26.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AstraZeneca is 183.21, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 140.95.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 17.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 9.95%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    AstraZeneca is a leading dividend payer. It pays a dividend yield of 3.89%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    AstraZeneca does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of AstraZeneca is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about AstraZeneca's dividend.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 17.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 9.95%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    AstraZeneca has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for AstraZeneca this week, compared to 7 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, AstraZeneca insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    40.87% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AstraZeneca's insider trading history.
Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZNCF Stock News Headlines

Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
AstraZeneca PLC (OTCMKTS:AZNCF) Sees Significant Drop in Short Interest
J.P. Morgan Remains a Buy on AstraZeneca (AZN)
See More Headlines

AZNCF Stock Analysis - Frequently Asked Questions

AstraZeneca's stock was trading at $134.45 at the beginning of 2024. Since then, AZNCF shares have increased by 11.2% and is now trading at $149.50.
View the best growth stocks for 2024 here
.

AstraZeneca's top institutional shareholders include Boston Common Asset Management LLC and Eagle Bay Advisors LLC.

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Ex-Dividend for 9/9 Dividend
8/07/2024
Dividend Payable
9/09/2024
Today
10/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:AZNCF
Fax
N/A
Employees
83,500
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (OTCMKTS:AZNCF) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners